The CASP9 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the human non-small cell lung carcinoma (NSCLC) epithelial cell line NCI-H1299, in which the gene encoding caspase-9 has been disrupted. This loss-of-function model enables investigation of intrinsic apoptosis signaling and caspase-9-dependent processes. The polyclonal format provides a heterogeneous gene-edited pool suitable for diverse functional assays.
The NCI-H1299 cell line was derived from a lymph node metastasis of lung carcinoma and is widely used as a model of metastatic lung adenocarcinoma. These cells exhibit characteristics of NSCLC, making them relevant for studying tumor progression, metastatic biology, and therapeutic response.
Caspase-9 serves as the initiator caspase of the mitochondrial apoptotic pathway. Upon apoptotic stimuli, pro-apoptotic Bcl-2 family members Bax and Bak promote cytochrome c release, which binds Apaf-1 to form the apoptosome. Procaspase-9 is recruited and activated within this complex, subsequently cleaving executioner caspases-3 and -7. These effector caspases target substrates such as PARP, lamins, and DFF45 to execute cell death. Caspase-9 activity is regulated upstream by p53-mediated transcription and Akt-mediated inhibitory phosphorylation. Post-mitochondrially, XIAP directly inhibits caspases-9, -3, and -7, whereas SMAC/DIABLO antagonizes XIAP. Chaperones Hsp70 and Hsp90 also interact with apoptosome components. CASP9 disruption therefore blocks the central protease cascade of intrinsic apoptosis.
In the NCI-H1299 metastatic lung cancer background, CASP9 knockout provides a powerful system to dissect apoptosis-dependent and -independent functions. This model is particularly valuable for studying resistance to apoptosis, a hallmark of NSCLC, and for evaluating drug responses. Non-apoptotic roles of caspase-9, such as in differentiation or inflammation, can also be examined without confounding apoptotic effects. Researchers can explore crosstalk with other cell death pathways and screen compounds that target the intrinsic apoptotic machinery.
Key applications include apoptosis assays (cytochrome c release, Annexin V/PI flow cytometry, caspase activity measurements), cell viability (MTT) and colony formation studies, and drug sensitivity screens. Western blotting for caspase-9, cleaved caspase-3, and substrate cleavage, along with mitochondrial membrane potential assessment (JC-1), facilitate mechanistic analyses. These polyclonal knockout cells are suited for screening pro-apoptotic compounds and investigating resistance mechanisms. For further details, contact Ascent Research.
